Dr Reddy’s Laboratories has announced the acquisition of select hormone therapy brands for the Indian market, signalling a strategic expansion within its speciality medicines portfolio.
The transaction strengthens the company’s presence in women’s healthcare while adding established products with existing physician adoption.
Investors are also monitoring the stock’s movement following the development.
Dr Reddy’s Laboratories entered into a definitive agreement with UK based Mercury Pharma Group Limited to acquire the trademarks Progynova and Cyclo Progynova, along with related assets, exclusively for India. The transaction involves a total consideration of USD 32.15 million.
The deal is domestic in scope and does not involve any share swap arrangement. The company clarified that the acquisition is not a related party transaction, and neither promoters nor group entities hold any interest in the seller.
The acquisition marks Dr Reddy’s entry into the hormone replacement therapy (HRT) segment in India. Progynova contains estradiol valerate and is prescribed for managing symptoms associated with oestrogen deficiency and for preventing post menopausal osteoporosis.
Cyclo Progynova combines oestrogen and progestogen components, designed to address hormone imbalance symptoms in eligible patients. By adding these therapies, the company aims to broaden its gynaecology offerings and strengthen its presence in specialised therapeutic categories.
The acquired brands already have established recognition among healthcare professionals in India. Industry data indicates that Progynova has recorded meaningful sales performance in recent periods, reflecting steady demand within the hormone therapy category.
Dr Reddy’s expects its existing distribution network and market access capabilities to support wider availability of these treatments. The move aligns with the company’s strategy of expanding branded formulations in therapeutic areas with consistent prescription demand.
Company leadership indicated that the acquisition supports long term growth within women’s healthcare. Management highlighted that integrating the brands into its portfolio could enhance patient access while reinforcing the company’s positioning in speciality therapies.
The transaction also reflects a broader industry trend where pharmaceutical firms strengthen niche portfolios through targeted brand acquisitions rather than large scale mergers.
Shares of Dr Reddy’s Laboratories Limited were trading at ₹1,286.50 as of 12:36 PM on February 19, 2026, rising ₹6.20 or 0.48% from the previous close of ₹1,280.30.
The stock opened at ₹1,290.00 and moved within an intraday range of ₹1,283.00 to ₹1,295.70, indicating measured trading activity following the announcement.
Dr Reddy’s acquisition of Progynova and Cyclo Progynova represents a focused expansion into hormone replacement therapy within the Indian market. By adding established brands to its gynaecology portfolio, the company aims to strengthen its speciality presence while leveraging existing commercial infrastructure.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Feb 19, 2026, 12:41 PM IST
Neha Dubey
Neha Dubey is a Content Analyst with 3 years of experience in financial journalism, having written for a leading newswire agency and multiple newspapers. At Angel One, she creates daily content on finance and the economy. Neha holds a degree in Economics and a Master’s in Journalism.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
